CASE REPORT
A 45-year-old Caucasian woman, with a history of rheumatoid arthritis, pre sented with a four week history of lethargy, night sweats and painful and enlarged gingivae. She was seen by a dentist and then her general medical practitioner and originally treated with oral antibiotics for presumed oral infec tion. Her condition deteriorated and she presented to hospital. The admitting physicians also noted the marked gin gival enlargement (Figs 1-2 on blood and bone marrow morphology (Fig. 3) and flow cytometry. The gingival enlargement improved rapidly on com mencing induction chemotherapy with daunorubicin, cytarabine and etoposide. This treatment was successful in achiev ing complete remission in the bone mar row. The patient has now completed four courses of chemotherapy. She remains in remission 18 months after diagnosis and the gingival enlargement and pain has resolved completely.
DISCUSSION
Acute onset gingival enlargement is an unusual physical sign with a narrow differential diagnosis. When approach ing a patient with gingival enlargement, a primary care practitioner should ini tially elucidate if the enlargement is old and chronic or new. Recent onset gingival enlargement can be second ary to a local cause, systemic illness or a drug reaction. A detailed drug history is paramount as the most common cause of recent onset gingival enlargement is drug therapy, having been reported with the use of phenytoin, 1 calcium channel blockers, 2 and cyclosporine. 3 Chronic gingivitis mainly secondary to poor oral hygiene is a common local cause of gingival enlargement. Systemic ill nesses such as Wegener's granuloma tosis, sarcoidosis, Crohn's disease and acromegaly 4 have also been described in association with gingival enlarge ment and signs and symptoms of these conditions must be actively sought when approaching such patients. AML is the most serious condition associated with gingival enlargement. In patients with AML other signs and symptoms of bone marrow failure such as mucosal ecchy moses and gingival bleeding and sys temic symptoms such as night sweats, recent infections and lethargy can accompany the gingival enlargement. A full blood count (FBC) is a simple and useful test in these circumstances and can help to reach a prompt diagnosis. In our case failure to recognise the signifi cance of the systemic symptoms led to a delay in the diagnosis that was poten tially life-threatening for the patient.
Gingival infiltration is a well known feature of the acute myeloid leukae mias but particularly those of myelo monoblastic and monoblastic lineages; subtypes M4 and M5 according to the French American British (FAB) clas sification. It is present in about 30% of patients at diagnosis with these AML subtypes. 5 These patients tend to present with a high white blood cell count and may also have skin infi ltrates, menin geal infiltrates or hepatosplenomegaly secondary to leukaemic blasts infi ltra tion. Extramedullary involvement is associated with CD56 expression on blast cells and karyotypic abnormalities involving chromosome 11, in particular abnormalities of 11q23 involving the MLL gene. [5] [6] [7] Our patient's cells, how ever, had normal cytogenetics and CD56 (a natural killer cell marker) was not aberrantly expressed.
AML is the most common myeloid leu kaemia with a prevalence of 3.8 cases per 100,000 with a median age at presenta tion of 70 years. It is a clonal disorder of haematopoietic stem cells. The disease causes a rapid onset of bone marrow failure causing anaemia, neutropenia and thrombocytopenia. Most cases arise in individuals without antecedent blood disorders but there is an increasing incidence of AML arising from myelo dysplastic syndromes and as a result of prior chemotherapy used to treat solid tumours. In patients younger than 60 years of age, cytotoxic chemotherapy might cure 20-75% of cases, accord ing primarily to prognostic risk groups attributed to the type of cytogenetic abnormality seen in the leukaemic cells. 8 Patients with AML who present with EMI at diagnosis, seem to have a lower com plete remission rate to induction chemo therapy and a lower overall survival rate. Therefore these patients may warrant an alternative therapeutic approach, includ ing stem cell transplant, to improve their outcome. [5] [6] [7] [8] It is imperative that acute myeloid leukaemia is diagnosed promptly. Early diagnosis allows the introduction of specific chemotherapy but also support ive treatment with blood products and early treatment of infection with broad spectrum intravenous antibiotics. Many patients present with cutaneous bleeding or bruising but some develop life threat ening gastrointestinal or intracerebral haemorrhage. Neutropenic fever is com mon. Septicaemia can be rapid in onset and may cause multiorgan failure before antibiotic therapy can be introduced. Early diagnosis of AML is therefore imperative and gingival enlargement may be an early physical sign to alert the clinician to this possibility.
